Onxeo S.A. buy metanicnor
Start price
11.03.19
/
50%
€0.89
Target price
12.03.19
€2.30
Performance (%)
0.00%
End price
12.03.19
€0.89
Summary
This prediction ended on 12.03.19 with a price of €0.89. metanicnor's BUY prediction for Onxeo S.A. closed unchanged from the start price. metanicnor has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | -0.678% | -0.678% | -65.831% | -84.141% |
| iShares Core DAX® | -1.822% | -1.170% | 11.771% | 12.805% |
| iShares Nasdaq 100 | -0.241% | 1.961% | 40.760% | 43.999% |
| iShares Nikkei 225® | -2.310% | -1.758% | 21.493% | 2.467% |
| iShares S&P 500 | -0.835% | 1.309% | 28.068% | 41.484% |